APA (7th ed.) Citation

G, S., M, M., I, C., U, K., S, K. B., G, C., . . . F, R. (2026). Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer. Cancer letters, 637, 218128. https://doi.org/10.1016/j.canlet.2025.218128

Chicago Style (17th ed.) Citation

G, Saorin, et al. "Nanoformulation of a Pin1 Inhibitor Potentiates the Efficacy of Liposomal Doxorubicin in Second-line Therapy for Ovarian Cancer." Cancer Letters 637 (2026): 218128. https://doi.org/10.1016/j.canlet.2025.218128.

MLA (9th ed.) Citation

G, Saorin, et al. "Nanoformulation of a Pin1 Inhibitor Potentiates the Efficacy of Liposomal Doxorubicin in Second-line Therapy for Ovarian Cancer." Cancer Letters, vol. 637, 2026, p. 218128, https://doi.org/10.1016/j.canlet.2025.218128.